Clinical Trial Update: Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 [Phase 3]

View source ↗

Summary

Phase 3 multicenter randomized trial comparing aflibercept to placebo for macular telangiectasia type 1 has been terminated. The document notes the trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Telangiectasia Type

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Macular Telangiectasia | Phase 3 | Status: TERMINATED